Transgenic Group Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
291
- Stock Symbol
-
2342
- Investments
-
12
- Share Price
-
$1.43
- (As of Thursday Closing)
Transgenic Group General Information
Description
Transgenic Group Inc formerly Trans Genic Inc is engaged in offering assistance of non-clinical experiments using large animals and general rearing management work, and non-clinical trial service using large animals. The company has two segments: Drug discovery support business, and Investment and consulting business.
Contact Information
Website
www.transgenic-group.co.jpCorporate Office
- 2-3-36 Tenjin
- Chuo-ku
- Fukuoka, 810-0001
- Japan
Corporate Office
- 2-3-36 Tenjin
- Chuo-ku
- Fukuoka, 810-0001
- Japan
Transgenic Group Stock Performance
As of 12-Nov-2026, Transgenic Group’s stock price is $1.43. Its current market cap is $23.9M with 16.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.43 | $1.35 | $1.24 - $3.12 | $23.9M | 16.7M | 49.3K | $0.01 |
Transgenic Group Financials Summary
As of 30-Jun-2026, Transgenic Group has a trailing 12-month revenue of $88.3M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 21,680 | 31,079 | 23,717 | 26,334 |
| Revenue | 88,306 | 87,407 | 85,281 | 90,549 |
| EBITDA | (66) | (2,615) | 1,667 | |
| Net Income | 206 | (513) | (7,145) | 28 |
| Total Assets | 60,080 | 60,900 | 64,062 | 64,823 |
| Total Debt | 16,091 | 13,067 | 17,208 | 14,683 |
Transgenic Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Transgenic Group Comparisons
Industry
Financing
Details
Transgenic Group Competitors (1)
One of Transgenic Group’s competitors is Chimeric Therapeutics, a Formerly VC-backed company based in Carlton, Australia.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Chimeric Therapeutics | Formerly VC-backed | Carlton, Australia |
Transgenic Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Transgenic Group Patents
Transgenic Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3978607-A1 | Exon-humanized mouse | Active | 27-May-2019 | ||
| EP-3978607-A4 | Exon-humanized mouse | Active | 27-May-2019 | ||
| EP-3978607-B1 | Exon-humanized mouse | Active | 27-May-2019 | ||
| EP-3978607-C0 | Exon-humanized mouse | Active | 27-May-2019 | ||
| JP-2023104002-A | Exon-humanized mouse | Pending | 27-May-2019 | C12N15/102 |
Transgenic Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Transgenic Group Investments & Acquisitions (12)
Transgenic Group’s most recent deal was a Merger/Acquisition with MASC Co. The deal was made on 16-Mar-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MASC Co | 16-Mar-2023 | Merger/Acquisition | Biotechnology | ||
| Lunapath Institute of Toxic Pathology | 01-Nov-2021 | Merger/Acquisition | Laboratory Services (Healthcare) | ||
| TGM (Distributors/Wholesale) | 01-Apr-2019 | Merger/Acquisition | Distributors/Wholesale | ||
| CURED (Biotechnology) | 20-Apr-2016 | Seed Round | Drug Discovery | ||
| Medicinal Chemistry Pharmaceutical | 24-Mar-2016 | Seed Round | Other Pharmaceuticals and Biotechnology |
Transgenic Group ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Transgenic Group Exits (4)
Transgenic Group’s most recent exit was on 01-Aug-2014 from GeneticLab. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| GeneticLab | 01-Aug-2014 | Completed |
|
||
| GeneticLab | 31-Jul-2013 | Completed |
|
||
| Kajitsudo | 20-Apr-2009 | Completed |
|
||
| Immunokick | 01-Mar-2004 | Joint Venture | Completed |
Transgenic Group Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| TG Business Services | Fukuoka City, Japan | 2017 | |
| Lunapath Institute of Toxic Pathology | Hamamatsu, Japan | 2011 | |
| TGM (Distributors/Wholesale) | Chiyoda-ku, Japan | 2003 | |
| Primmune | Kobe, Japan | 2000 | |
| GeneticLab | Sapporo, Japan | 2000 |
Transgenic Group FAQs
-
When was Transgenic Group founded?
Transgenic Group was founded in 1998.
-
Where is Transgenic Group headquartered?
Transgenic Group is headquartered in Fukuoka, Japan.
-
What is the size of Transgenic Group?
Transgenic Group has 291 total employees.
-
What industry is Transgenic Group in?
Transgenic Group’s primary industry is Biotechnology.
-
Is Transgenic Group a private or public company?
Transgenic Group is a Public company.
-
What is Transgenic Group’s stock symbol?
The ticker symbol for Transgenic Group is 2342.
-
What is the current stock price of Transgenic Group?
As of 12-Nov-2026 the stock price of Transgenic Group is $1.43.
-
What is the current market cap of Transgenic Group?
The current market capitalization of Transgenic Group is $23.9M.
-
What is Transgenic Group’s current revenue?
The trailing twelve month revenue for Transgenic Group is $88.3M.
-
Who are Transgenic Group’s competitors?
Chimeric Therapeutics is a competitor of Transgenic Group.
-
What is Transgenic Group’s annual earnings per share (EPS)?
Transgenic Group’s EPS for 12 months was $0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
